FDA Approves Labeling With Abuse-Deterrent Features for Third Extended-Release Opioid Analgesic

The FDA has approved new labeling for Embeda extended-release capsules , an opioid analgesic for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Embeda is the third ER opioid analgesic to be approved with labeling describing the product's abuse-deterrent properties consistent with the FDA's 2013 draft guidance.

http://ift.tt/1DtHJOv